At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 5 enrolled
Drug / intervention
Alefaceptdrug
Likely dose
Alefacept 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 4 clinical trial evaluating Alefacept for Atopic Dermatitis. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This study will assess the safety, tolerability, and efficacy of Alefacept in patient with moderate to severe atopic dermatitis who could not be adequately controlled with topical therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc.
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2009
Primary CompletionSep 2009
Study CompletionOct 2009
TodayJul 2026
First PostedJan 30, 2009
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.4 years ago
Interventions
Alefaceptdrug
Alefacept 15mg IM every week for 12 weeks